Our Developed Europe business is made up of operations in Europe’s major developed countries. The Anaesthetics and Thrombosis portfolios are the leading therapeutic focused brands in Developed Europe.
The API site at Oss, supported by its satellite operation at Sioux City, supplies APIs worldwide. The Notre Dame de Bondeville and Bad Oldesloe sites are strategically important manufacturers for the Group.
Contribution to Group revenue
Revenue contribution - by therapeutic category
- The injectable anticoagulants category in Developed Europe recorded flat volume growth and made up 75% of the total anticoagulants (injectables and orals).
- The Anaesthetics category in Developed Europe grew 1,1% by value across all products to EUR1,3 billion as at 30 May 2018. General anaesthetics made up 50,3% of total value and grew 3,7% for the year.
Source: May 2018 IMS
Number of products launched:
IMS value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years
3 – 5 years
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
Number of permanent employees:
|Revenue – R’billion||2018||2017 (CER)||% change|
|Total||12 329||11 871||4|
|Commercial Pharmaceuticals||7 434||6 941||7|
|Anaesthetics||2 170||1 732||25|
|Thrombosis||3 471||3 204||8|
|High Potency & Cytotoxics||1 417||1 529||(7)|
|Manufacturing||4 895||4 930||(1)|
|– API||4 259||4 263||0|
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.